The present retrospective study evaluated very older (>80 years) women with OAB who were discontinued anticholinergic drugs by the other departments between May 2018 and January 2021. For the study, ethical approval was obtained from our local ethical committee (number: 2022/113).
The inclusion criteria were as follows: patients who are >80 years old, presence of complaints for at least three months, presence of uncomplicated OAB symptoms (not requiring invasive urodynamic tests including multichannel cystometry and pressure flow studies, ambulatory monitoring, and video urodynamics), presence of a history of using at least one anticholinergic alone or as part of combination therapy and the discontinue of the anticholinergic drugs by the other departments (internal medicine, neurology, and geriatric) due to drug interaction, increase in side effect profile, inability to comply with medication, presence of the history using mirabegron (50 mg per day) alone for at least 12 weeks after the discontinued anticholinergic therapy, presence of an evaluation using the Overactive Bladder-Validated Eight-Question (OAB-V8) form before and after medication.
The cutoff age was 80 years and over because the current literature used this value [10 (link),11 (link)]. Efficacy assessments were performed using OAB-V8 scores before and after mirabegron monotherapy (12 weeks) [12 ]. Safety was evaluated based on adverse events (hypertension, nasopharyngitis, and urinary tract infection), electrocardiography, and hypertension measure. None of the patients in the study did have a Mini-Mental State Examination (MMSE) score. It may be explained by the retrospective nature of the study. Information about the patients was collected from the medical records system of the hospital. Patient data including demographic characteristics, diagnoses, values before and after mirabegron monotherapy, and adverse events were evaluated.
Statistical analysis
All data in both groups were compared using Statistical Package for Social Sciences (SPSS) version 25.0 (IBM SPSS Statistics, Armonk, NY, USA) for Windows. Continuous variables were represented as mean ± standard deviation and median ± range (minimum-maximum), and categorical variables were represented as numbers and percentages. A chi-squared test (Fisher’s exact test) was used to compare categorical variables (before and after mirabegron monotherapy). The Mann-Whitney U test was used for non-categorical variables. p < 0.05 was considered to be the threshold for statistical significance.
The inclusion criteria were as follows: patients who are >80 years old, presence of complaints for at least three months, presence of uncomplicated OAB symptoms (not requiring invasive urodynamic tests including multichannel cystometry and pressure flow studies, ambulatory monitoring, and video urodynamics), presence of a history of using at least one anticholinergic alone or as part of combination therapy and the discontinue of the anticholinergic drugs by the other departments (internal medicine, neurology, and geriatric) due to drug interaction, increase in side effect profile, inability to comply with medication, presence of the history using mirabegron (50 mg per day) alone for at least 12 weeks after the discontinued anticholinergic therapy, presence of an evaluation using the Overactive Bladder-Validated Eight-Question (OAB-V8) form before and after medication.
The cutoff age was 80 years and over because the current literature used this value [10 (link),11 (link)]. Efficacy assessments were performed using OAB-V8 scores before and after mirabegron monotherapy (12 weeks) [12 ]. Safety was evaluated based on adverse events (hypertension, nasopharyngitis, and urinary tract infection), electrocardiography, and hypertension measure. None of the patients in the study did have a Mini-Mental State Examination (MMSE) score. It may be explained by the retrospective nature of the study. Information about the patients was collected from the medical records system of the hospital. Patient data including demographic characteristics, diagnoses, values before and after mirabegron monotherapy, and adverse events were evaluated.
Statistical analysis
All data in both groups were compared using Statistical Package for Social Sciences (SPSS) version 25.0 (IBM SPSS Statistics, Armonk, NY, USA) for Windows. Continuous variables were represented as mean ± standard deviation and median ± range (minimum-maximum), and categorical variables were represented as numbers and percentages. A chi-squared test (Fisher’s exact test) was used to compare categorical variables (before and after mirabegron monotherapy). The Mann-Whitney U test was used for non-categorical variables. p < 0.05 was considered to be the threshold for statistical significance.
Free full text: Click here
